| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 09/28/2011 | CN102198081A Leptin gel slow-release system and application thereof |
| 09/28/2011 | CN101838323B Anti-platelet thrombolysin and preparation method thereof |
| 09/28/2011 | CN101745118B Cell cytokine for treatment of Alzheimer |
| 09/28/2011 | CN101745103B Normal-temperature preserved albumin preparation |
| 09/28/2011 | CN101597291B 2-aminoacyl tryptophyl-Beta-tetrahydric carboline-3-carboxylic acid carbobenzoxy as well as preparation method and application thereof |
| 09/28/2011 | CN101524529B Treatment on human malignant solid tumor by HNF4 alpha inducement and differentiation |
| 09/28/2011 | CN101417121B Medicine capable of curing skin burning and freezing injury |
| 09/28/2011 | CN101333531B CXCR4 antagonist recombination protein SDF-1 beta P2G, preparation method and application thereof |
| 09/28/2011 | CN101307094B Novel nuclear factor -kappa B p65 subunit antagonizing polypeptide |
| 09/27/2011 | US8026353 Nucleotide sequences coding proteins for use in the treatment autoimmune and immunological diseases |
| 09/27/2011 | US8026346 Tribonectins |
| 09/27/2011 | US8026341 Transfection complexes |
| 09/27/2011 | US8026230 Methods and compositions for treating cancer using proteasome inhibitors |
| 09/27/2011 | US8026223 Treating malignant tumors with high field strength electroporation of plasmids encoding IL-12 |
| 09/27/2011 | US8026218 Bifunctional analgesic compounds for opioid receptor agonists and neurokinin-1 receptor antagonists |
| 09/27/2011 | US8026217 Compositions and methods for treating neural anoxia and spreading depression |
| 09/27/2011 | US8026216 Using endothelin B (ETB) agonist to enhance the delivery and resulting efficacy of chemotherapeutic agent; antitumor agents |
| 09/27/2011 | US8026215 Methods and compositions for control of fetal growth via modulation of relaxin |
| 09/27/2011 | US8026214 Liquid, aqueous pharmaceutical compositions of factor VII polypeptides |
| 09/27/2011 | US8026213 Methods for treating muscle diseases and disorders |
| 09/27/2011 | US8026212 Methods of preparing pharmaceutical compositions comprising GPR119 agonists having the effect of glucose-dependent insulinotropic peptide secretatgogues |
| 09/27/2011 | US8026211 Methods and formulations for increasing intestinal function |
| 09/27/2011 | US8026210 Exendins and exendin agonist analogs to regulate gastrointestinal motility |
| 09/27/2011 | US8026209 Administering a diagnostic agent with a carrier conjugated to a targeting molecule that binds to a lipopolysaccharide-sensitive polypeptide, which is either up-regulated or down-regulated in ECs by exposure to LPS; delivery into the EC vascular barrier and/or across the EC vascular barrier |
| 09/27/2011 | US8026208 Peptide tyrosinase inhibitors and uses thereof |
| 09/27/2011 | US8026207 Peptides and compositions for inhibiting fungal growth |
| 09/27/2011 | US8026072 Method of identifying compounds that bind BAFF-R |
| 09/27/2011 | US8025909 Use of herbs in hair relaxation |
| 09/27/2011 | US8025900 Drug incorporated into carrier substrate of hyaluronic acid, amino acid or polyoxyalkylene glycol |
| 09/27/2011 | US8025898 Enhanced drug delivery in transdermal systems |
| 09/27/2011 | US8025891 Porin B (PorB) as a therapeutic target for prevention and treatment of infection by Chlamydia |
| 09/27/2011 | US8025889 Botulinum toxin administration to treat various conditions |
| 09/27/2011 | US8025886 Modified VEGF-A with improved angiogenic properties |
| 09/27/2011 | US8025883 Antagonists and methods for inhibiting angiogenesis |
| 09/27/2011 | US8025876 Antibodies against a peptide epitope of apolipoprotein B |
| 09/27/2011 | US8025872 Osteogenic synthetic peptides, pharmaceutical compositions comprising the same, and medium containing the same |
| 09/27/2011 | CA2608848C Fad4, fad5, fad5-2, and fad6, novel fatty acid desaturase family members and uses thereof |
| 09/27/2011 | CA2537421C Peptides and compounds that bind to thrombopoietin receptor |
| 09/27/2011 | CA2510313C Saposin c and receptors as targets for treatment of benign and malignant disorders |
| 09/27/2011 | CA2506476C Method of treatment of myocardial infarction |
| 09/27/2011 | CA2503982C Sincalide formulations |
| 09/27/2011 | CA2501751C A combination therapy for hiv infections |
| 09/27/2011 | CA2498512C Metal implant coated under reduced oxygen concentration with osteoinductive protein |
| 09/27/2011 | CA2490309C Anthelmintic oral homogeneous veterinary pastes |
| 09/27/2011 | CA2485472C Gh secretagogues and uses thereof |
| 09/27/2011 | CA2468849C Surface simulation synthetic peptides useful in the treatment of hyper-variable viral pathogens |
| 09/27/2011 | CA2467723C Method for treating cervical cancer |
| 09/27/2011 | CA2463865C Dimeric compounds and their use as anti-viral agents |
| 09/27/2011 | CA2408034C Recombinant sequence, its preparation and use |
| 09/27/2011 | CA2405811C Novel use of pulmonary surfactant for the prophylaxis or early treatment of acute pulmonary diseases |
| 09/27/2011 | CA2377519C Compositions containing soluble forms of hla-g for treating inflammatory skin pathologies |
| 09/27/2011 | CA2351015C Novel system for regulating transgene expression |
| 09/27/2011 | CA2336218C Neurotrophic factors |
| 09/27/2011 | CA2213331C Chemokine receptors 88-2b [ckr-3] and 88c and their antibodies |
| 09/22/2011 | WO2011116291A1 Production of human c1 inhibitor in human cells |
| 09/22/2011 | WO2011116286A2 Stable bortezomib formulations |
| 09/22/2011 | WO2011116245A2 Methods of treating inflammation |
| 09/22/2011 | WO2011116007A1 Combination therapies using cyclosporine and aromatic cationic peptides |
| 09/22/2011 | WO2011115871A1 Pharmaceutical compositions of growth hormone secretagogue receptor ligands |
| 09/22/2011 | WO2011115728A2 Polynucleotides that stimulate neutrophils |
| 09/22/2011 | WO2011115712A2 Tfpi inhibitors and methods of use |
| 09/22/2011 | WO2011115688A2 Integrin interaction inhibitors for the treatment of cancer |
| 09/22/2011 | WO2011115651A2 Natural plant products for control of cancer metastasis |
| 09/22/2011 | WO2011115562A1 Antimicrobial compound |
| 09/22/2011 | WO2011115447A2 C-terminal truncated peroxiredoxin-ii, and composition for preventing and treating apoptosis containing same |
| 09/22/2011 | WO2011115272A1 Proteoglycan-containing microneedle array |
| 09/22/2011 | WO2011115264A1 Composition for transnasal administration and method for producing same |
| 09/22/2011 | WO2011115225A1 Periodontal-disease-specific peptide, and treatment and diagnosis of periodontal disease using same |
| 09/22/2011 | WO2011115106A1 Pharmaceutical for pseudo-exercise therapy |
| 09/22/2011 | WO2011114645A1 Anti-allergic composition |
| 09/22/2011 | WO2011114225A1 Beta-propiolactone for inactivation of viruses in pharmaceutical pancreatic enzyme preparations |
| 09/22/2011 | WO2011114224A1 Gastro-resistant enzyme pharmaceutical compositions |
| 09/22/2011 | WO2011114071A2 Synthetic cyclopeptide, preparation process and uses |
| 09/22/2011 | WO2011113882A1 Diagnosis and treatment of cancer based on avl9 |
| 09/22/2011 | WO2011113825A1 Use of urodilatin for preparing a medicament for the treatment of cardiovascular, renal, pulmonary and neuronal syndromes while avoiding a rebound |
| 09/22/2011 | WO2011113819A2 Novel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| 09/22/2011 | WO2011113641A1 Complement factor h for oxidative stress disease conditions |
| 09/22/2011 | WO2011113604A1 Peptides or antibodies which bind to melanoma inhibitory activity (mia) protein |
| 09/22/2011 | WO2011094765A3 A targeting signal for integrating proteins, peptides and biological molecules into bacterial microcompartments |
| 09/22/2011 | WO2011066369A3 Antagonists of il-6 to raise albumin and/or lower crp |
| 09/22/2011 | WO2011056477A3 Methods for treating inflammation and oxidative stress related diseases |
| 09/22/2011 | WO2011055980A3 Composite of a protein comprising zinc oxide-bonding peptides and zinc oxide nanoparticles, and use thereof |
| 09/22/2011 | WO2011053750A3 Drug resistant immunotherapy for treatment of a cancer |
| 09/22/2011 | WO2011050178A3 Targeted prdm gene or protein modulation therapeutic agents |
| 09/22/2011 | WO2011008274A3 Reduced volume formulation of glatiramer acetate and methods of administration |
| 09/22/2011 | WO2007127834A3 Compositions and methods of preparation thereof |
| 09/22/2011 | US20110231942 Tiki1 and tiki2, wnt inhibitors |
| 09/22/2011 | US20110230865 Sustained delivery of an active agent using an implantable system |
| 09/22/2011 | US20110230652 Use of lipid conjugates in the treatment of diseases |
| 09/22/2011 | US20110230637 Modified human thymic stromal lymphopoietin |
| 09/22/2011 | US20110230448 Treatment and/or Prevention of Non-Viral Epithelial Damage |
| 09/22/2011 | US20110230427 Materials and methods for stabilizing nanoparticles in salt solutions |
| 09/22/2011 | US20110230426 Template-fixed peptidomimetics |
| 09/22/2011 | US20110230425 Compositions for protection and cellular delivery of interfering rna |
| 09/22/2011 | US20110230424 Ophthalmic solutions, including contact lens care and eye drops comprising carnosine, preferably in combination with dexpanthenol and/or hyaluronic acid |
| 09/22/2011 | US20110230423 Therapy and medicament using integrin ligands for treating cancer |
| 09/22/2011 | US20110230422 Purging of an ex vivo hematopoietic stem cell culture of cancer cells |
| 09/22/2011 | US20110230421 Fusion proteins of apoptin-protein transduction domain of carboxyl-terminus of ec-sod |
| 09/22/2011 | US20110230420 Releasable conjugates for nucleic acids delivery systems |
| 09/22/2011 | US20110230419 Iap binding compounds |